Ipamorelin: Selective Growth Hormone Secretagogue Research
For Research Purposes Only. Not intended for human consumption.
Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue. It has been studied extensively for its ability to stimulate GH release through the ghrelin receptor while demonstrating a high degree of selectivity compared to earlier generation secretagogues.
What Is Ipamorelin?
Ipamorelin belongs to the class of growth hormone secretagogues — compounds that stimulate GH release through mechanisms distinct from GHRH. It acts as an agonist at the ghrelin receptor (GHS-R1a), mimicking the action of the endogenous hormone ghrelin. Its development represented an advance over earlier secretagogues due to its apparent selectivity profile.
Key Research Areas
Selectivity research has been central to Ipamorelin studies. Unlike some earlier GH secretagogues, Ipamorelin has shown high selectivity for GH release with minimal stimulation of cortisol, prolactin, and ACTH in preclinical studies. This selectivity profile has made it a subject of continued research interest.
GH pulse research has examined how Ipamorelin affects the amplitude and frequency of GH secretion pulses. Studies have observed dose-dependent increases in GH pulse amplitude without significantly altering pulse frequency, suggesting a distinct mechanism compared to GHRH analogs.
Combination protocol research has examined Ipamorelin in combination with GHRH analogs such as CJC-1295, investigating whether the two mechanisms produce synergistic effects on GH secretion in animal models.
Bone density research has examined the downstream effects of Ipamorelin-stimulated GH elevation on bone mineral density markers in animal models, generating interest in its effects on skeletal tissue.
Research Specifications
Zyvara Labs Ipamorelin is synthesized as a lyophilized powder with ≥99% purity verified by independent HPLC and mass spectrometry. Lot-specific COA available in our COA Library.
Disclaimer
This post summarizes publicly available preclinical research. Ipamorelin has not been evaluated or approved by the FDA. For laboratory research use only.